The newly onset anti-MDA5-DM patients admitted to our center from June 1, 2018 to August 31, 2021 were followed-up for a median of 15 months in order to further explore the prognosis-related risk factors of anti-MDA5-DM and to provide a basis for risk stratification of such patients. This evidence concerns the gene IFIH1 and dermatomyositis.